A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era

作者：Hosein Peter J; Maragulia Jocelyn C; Salzberg Matthew P; Press Oliver W; Habermann Thomas M; Vose Julie M; Bast Martin; Advani Ranjana H; Tibshirani Robert; Evens Andrew M; Islam Nahida; Leonard John P; Martin Peter; Zelenetz Andrew D; Lossos Izidore S^*

来源：British Journal of Haematology, 2014, 165(3): 358-363.

DOI：10.1111/bjh.12753

• diffuse large B-cell lymphoma
• lymphoma
• rituximab
• central nervous system
• breast

Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system (CNS) relapses. Data was retrospectively collected on patients from 8 US academic centres. Only patients with stage I/II disease (involvement of breast and localized lymph nodes) were included. Histologies apart from primary DLBCL were excluded. Between 1992 and 2012, 76 patients met the eligibility criteria. Most patients (86%) received chemotherapy, and 69% received immunochemotherapy with rituximab; 65% received radiation therapy and 9% received prophylactic CNS chemotherapy. After a median follow-up of 4 center dot 5years (range 0 center dot 6-20 center dot 6years), the Kaplan-Meier estimated median progression-free survival was 10 center dot 4years (95% confidence interval [CI] 5 center dot 8-14 center dot 9years), and the median overall survival was 14 center dot 6years (95% CI 10 center dot 2-19years). Twelve patients (16%) had CNS relapse. A low stage-modified International Prognostic Index (IPI) was associated with longer overall survival. Rituximab use was not associated with a survival advantage. Primary breast DLBCL has a high rate of CNS relapse. The stage-modified IPI score is associated with survival.

• 出版日期2014-5